Literature DB >> 9311872

Toward a poliovirus-based simian immunodeficiency virus vaccine: correlation between genetic stability and immunogenicity.

S Tang1, R van Rij, D Silvera, R Andino.   

Abstract

Recombinant polioviruses expressing foreign antigens may provide a convenient vaccine vector to engender mucosal immunity. Replication-competent chimeric viruses can be constructed by fusing foreign antigenic sequences to several positions within the poliovirus polyprotein. Artificial cleavage sites ensure appropriate proteolytic processing of the recombinant polyprotein, yielding mature and functional viral proteins. To study the effect of the position of insertion, two different recombinant polioviruses were examined. A small amino-terminus insertion delayed virus maturation and produced a thermosensitive particle. In contrast, insertion at the junction between the P1 and P2 regions yielded a chimeric poliovirus that replicated like the wild type. Eight different chimeras were constructed by inserting simian immunodeficiency virus (SIV) sequences at the P1/P2 junction. All recombinant viruses replicated with near-wild-type efficiency in tissue culture cells and expressed high levels of the SIV antigens. One of the inserted fragments corresponding to gp41 envelope protein was N-glycosylated but was not secreted. Inserted sequences were only partially retained after few rounds of replication in HeLa cells. This problem could be remedied to some extent by altering the sequences flanking the insertion point. Reducing the homology of the direct repeats by 37% decrease the propensity of the recombinant viruses to delete the insert. To determine the immunogenic potential of the recombinants, mice susceptible to poliovirus infection were inoculated intraperitoneally. The antibody titers elicited against Gag p17 depended on the viral doses and the number of inoculations. In addition, recombinants which display higher genetic stability were more effective in inducing an immune response against the SIV antigens, and inoculation with a mix of recombinants carrying different SIV antigens (a cocktail of recombinants) elicited humoral responses against each of the individual SIV sequences.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9311872      PMCID: PMC192139          DOI: 10.1128/JVI.71.10.7841-7850.1997

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  28 in total

1.  Myristate-protein interactions in poliovirus: interactions of VP4 threonine 28 contribute to the structural conformation of assembly intermediates and the stability of assembled virions.

Authors:  N Moscufo; M Chow
Journal:  J Virol       Date:  1992-12       Impact factor: 5.103

2.  A study of poliovaccination in infancy: excretion following challenge with live virus by children given killed or living poliovaccine.

Authors:  J L Henry; E S Jaikaran; J R Davies; A J Tomlinson; P J Mason; J M Barnes; A J Beale
Journal:  J Hyg (Lond)       Date:  1966-03

3.  Poliovirus replicons that express the gag or the envelope surface protein of simian immunodeficiency virus SIV(smm) PBj14.

Authors:  M J Anderson; D C Porter; P N Fultz; C D Morrow
Journal:  Virology       Date:  1996-05-01       Impact factor: 3.616

4.  Slowing the spread of HIV: agenda for the 1990s.

Authors:  M H Merson
Journal:  Science       Date:  1993-05-28       Impact factor: 47.728

Review 5.  How does HIV cause AIDS?

Authors:  R A Weiss
Journal:  Science       Date:  1993-05-28       Impact factor: 47.728

6.  Protection of macaques against SIV infection by subunit vaccines of SIV envelope glycoprotein gp160.

Authors:  S L Hu; K Abrams; G N Barber; P Moran; J M Zarling; A J Langlois; L Kuller; W R Morton; R E Benveniste
Journal:  Science       Date:  1992-01-24       Impact factor: 47.728

Review 7.  Development of a vaccine for the prevention of AIDS, a critical appraisal.

Authors:  D T Karzon; D P Bolognesi; W C Koff
Journal:  Vaccine       Date:  1992       Impact factor: 3.641

8.  HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease.

Authors:  G Pantaleo; C Graziosi; J F Demarest; L Butini; M Montroni; C H Fox; J M Orenstein; D P Kotler; A S Fauci
Journal:  Nature       Date:  1993-03-25       Impact factor: 49.962

9.  Enhanced immunity to human immunodeficiency virus (HIV) envelope elicited by a combined vaccine regimen consisting of priming with a vaccinia recombinant expressing HIV envelope and boosting with gp160 protein.

Authors:  E L Cooney; M J McElrath; L Corey; S L Hu; A C Collier; D Arditti; M Hoffman; R W Coombs; G E Smith; P D Greenberg
Journal:  Proc Natl Acad Sci U S A       Date:  1993-03-01       Impact factor: 11.205

10.  Poliovirus RNA synthesis utilizes an RNP complex formed around the 5'-end of viral RNA.

Authors:  R Andino; G E Rieckhof; P L Achacoso; D Baltimore
Journal:  EMBO J       Date:  1993-09       Impact factor: 11.598

View more
  22 in total

1.  Changing the surface of a virus shell fusion of an enzyme to polyoma VP1.

Authors:  S Gleiter; K Stubenrauch; H Lilie
Journal:  Protein Sci       Date:  1999-12       Impact factor: 6.725

2.  Coxsackievirus expression of the murine secretory protein interleukin-4 induces increased synthesis of immunoglobulin G1 in mice.

Authors:  N M Chapman; K S Kim; S Tracy; J Jackson; K Höfling; J S Leser; J Malone; P Kolbeck
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

3.  Viable polioviruses that encode 2A proteins with fluorescent protein tags.

Authors:  Natalya L Teterina; Eric A Levenson; Ellie Ehrenfeld
Journal:  J Virol       Date:  2009-11-25       Impact factor: 5.103

4.  Characterization of recombinant hepatitis A virus genomes containing exogenous sequences at the 2A/2B junction.

Authors:  M R Beard; L Cohen; S M Lemon; A Martin
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

5.  Expression of brain-derived neurotrophic factor in the central nervous system of mice using a poliovirus-based vector.

Authors:  Qingmei Jia; Fengyi Liang; Seii Ohka; Akio Nomoto; Tsutomu Hashikawa
Journal:  J Neurovirol       Date:  2002-02       Impact factor: 2.643

6.  Expression of an antigenic adenovirus epitope in a group B coxsackievirus.

Authors:  K Höfling; S Tracy; N Chapman; K S Kim; J Smith Leser
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

Review 7.  Emergency Services of Viral RNAs: Repair and Remodeling.

Authors:  Vadim I Agol; Anatoly P Gmyl
Journal:  Microbiol Mol Biol Rev       Date:  2018-03-14       Impact factor: 11.056

8.  Protection against simian immunodeficiency virus vaginal challenge by using Sabin poliovirus vectors.

Authors:  S Crotty; C J Miller; B L Lohman; M R Neagu; L Compton; D Lu; F X Lü; L Fritts; J D Lifson; R Andino
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

9.  Novel design architecture for genetic stability of recombinant poliovirus: the manipulation of G/C contents and their distribution patterns increases the genetic stability of inserts in a poliovirus-based RPS-Vax vector system.

Authors:  Sang-Gu Lee; Dae-You Kim; Byung-Hwa Hyun; Yong-Soo Bae
Journal:  J Virol       Date:  2002-02       Impact factor: 5.103

10.  Simian immunodeficiency virus promoter exchange results in a highly attenuated strain that protects against uncloned challenge virus.

Authors:  Philippe Blancou; Nicole Chenciner; Raphaël Ho Tsong Fang; Valérie Monceaux; Marie-Christine Cumont; Denise Guétard; Bruno Hurtrel; Simon Wain-Hobson
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.